Fulvia baldinotti

Dr. Fulvia baldinotti


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2008 in Journal of Andrology
Verified
Journal Article
Open access
PDF file
FBFulvia baldinotti
Fulvia baldinotti
SMS. Majore
S. Majore
AFA. Fogli
A. Fogli
GMG. Marrocco
G. Marrocco
PGP. Ghirri
P. Ghirri
PGP. Grammatico
P. Grammatico
Steroid 5α‐reductase (5αR) deficiency (OMIM number #264600) is a rare 46,XY disorder of sex differentiation caused by mutations in the 5αR type 2 gene (SRD5A2) resulting in dihydrotestosterone deficiency during fetal development. We report on the analysis of the SRD5A2 gene in 6 unrelated 46,XY Italian patients with external genitalia morphology ranging from predominantly female to nearly completely male. Three subjects were seen and assessed at birth, 1 patient was referred to us before puberty, and 2 at postpubertal age. Six different causative mutations (5 missense and 1 nonsense) and a rare polymorphism were identified. Four patients presented homozygous single‐base substitutions. These SRD5A2 mutations were located in exon 2 (variant Cys133Gly), exon 4 (Gly196Ser and Ala207Asp) and exon 5 (Tyr235Phe). A fifth subject was a compound heterozygote who carried a nonsense mutation in exon 1 (Trp53X) and a second SRD5A2 alteration in exon 5 (Tyr235Phe). The final patient presented a mutation in only 1 allele (Gly34Trp) together with the Ala49Thr variant. The molecular characterization of these patients made it possible to identify novel mutations and to confirm, before gender assignment or any surgical approach, the suspected 5αR deficiency in 2 newborns, 1 of whom had inconclusive hormonal data. 5αR deficiency in subjects without parental consanguinity and the presence of compound heterozygotic patients suggest that SRD5A2 mutations carrier frequency may be higher than previously thought.

6 May 2020 in Journal of Endocrinological Investigation
Verified
Journal Article
Closed access
PDF file
GCGiorgio Costagliola
Giorgio Costagliola
MCM. Cosci o di Coscio
M. Cosci o di Coscio
BMB. Masini
B. Masini
FBFulvia baldinotti
Fulvia baldinotti
Maria CaligoMaria Caligo
Maria Caligo
Silvano BertelloniSilvano Bertelloni
Silvano Bertelloni

12 November 2023 in Genes
Verified
Journal Article
Open access
PDF file
VBVeronica Bertini
Veronica Bertini
FBFulvia baldinotti
Fulvia baldinotti
Pietro ParmaPietro Parma
Pietro Parma
NTNina Tyutyusheva
Nina Tyutyusheva
MSMargherita Sepich
Margherita Sepich
Silvano BertelloniSilvano Bertelloni
Silvano Bertelloni
Disorders of sexual development (DSDs) encompass a group of congenital conditions associated with atypical development of internal and external genital structures. Among those with DSDs are 46,XX males, whose condition mainly arises due to the translocation of SRY onto an X chromosome or an autosome. In the few SRY-negative 46,XX males, overexpression of other pro-testis genes or failure of pro-ovarian/anti-testis genes may be involved, even if a non-negligible number of cases remain unexplained. A three-year-old boy with an SRY-negative 46,XX karyotype showed a normal male phenotype and normal prepubertal values for testicular hormones. A heterozygous de novo in tandem duplication of 50,221 bp, which encompassed exons 2 and 3 of the Doublesex and Mab-3-related transcription factor 1 (DMRT1) gene, was detected using MPLA, CGH-array analysis, and Sanger sequencing. Both breakpoints were in the intronic regions, and this duplication did not stop or shift the coding frame. Additional pathogenic or uncertain variants were not found in a known pro-testis/anti-ovary gene cascade using a custom NGS panel and whole genome sequencing. The duplication may have allowed DMRT1 to escape the transcriptional repression that normally occurs in 46,XX fetal gonads and thus permitted the testicular determination cascade to switch on. So far, no case of SRY-negative 46,XX DSD with alterations in DMRT1 has been described.

1 January 2002 in International Journal of Oncology
Verified
Journal Article
Closed access
PDF file
LBLaura Boldrini
Laura Boldrini
PFPinuccia Faviana
Pinuccia Faviana
SGS. Gisfredi
S. Gisfredi
DQD. Di Quirico
D. Di Quirico
MLMarco Lucchi
Marco Lucchi
GFGabriella Fontanini
Gabriella Fontanini

28 March 2012
Verified
Book Chapter
Open access
PDF file
SLS. Lunardi
S. Lunardi
FFF. Forli
F. Forli
AMA. Michelucci
A. Michelucci
ALA. Liumbruno
A. Liumbruno
FBFulvia baldinotti
Fulvia baldinotti
PGP. Ghirri
P. Ghirri

25 September 2023 in Sexes
Verified
Journal Article
Open access
PDF file
GBGiulia Bertolucci
Giulia Bertolucci
NTNina Tyutyusheva
Nina Tyutyusheva
MSMargherita Sepich
Margherita Sepich
FBFulvia baldinotti
Fulvia baldinotti
Maria CaligoMaria Caligo
Maria Caligo
Silvano BertelloniSilvano Bertelloni
Silvano Bertelloni
Congenital adrenal hyperplasia (CAH) is a heterogeneous group of autosomal recessive disorders due to defects in adrenal steroid biosynthesis. In about 90% of patients, CAH is caused by pathogenetic variants in CYP21A2 gene, impairing the function of 21-hydroxylase (21-OH) enzyme. CAH can present as classical form (simple virilizing or salt wasting) or as non-classical form (NC-CAH). NC-CAH is due to pathogenetic variants in the CYP21A2 gene that result in 20–70% residual activity of 21-hydroxylase. Early diagnosis may be missed, mainly in childhood, jeopardizing long-term outcome. This paper will review some information on clinical findings, symptoms, diagnostic approaches, and treatments of NC-CAH in childhood, allowing better management and long-term outcome.